This is a Validated Antibody Database (VAD) review about Rhesus mon.. PDCD1, based on 80 published articles (read how Labome selects the articles), using PDCD1 antibody in all methods. It is aimed to help Labome visitors find the most suited PDCD1 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
PDCD1 synonym: PD1; programmed cell death protein 1

BioLegend
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 3b
BioLegend PDCD1 antibody (Biolegend, 329920) was used in flow cytometry on human samples (fig 3b). Cell Rep (2019) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 2b
BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on human samples (fig 2b). Front Immunol (2019) ncbi
mouse monoclonal (EH12.2H7)
  • mass cytometry; human; loading ...; fig 2b
BioLegend PDCD1 antibody (Biolegend, 329902) was used in mass cytometry on human samples (fig 2b). Cell (2019) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 4a
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples (fig 4a). J Virol (2019) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 5d, 5e
BioLegend PDCD1 antibody (BioLegend, 329920) was used in flow cytometry on human samples (fig 5d, 5e). Cell (2018) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig s1d
BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on human samples (fig s1d). Proc Natl Acad Sci U S A (2018) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; 1:100; loading ...
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples at 1:100. Nature (2018) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 4c
BioLegend PDCD1 antibody (Biolegend, 329906) was used in flow cytometry on human samples (fig 4c). J Clin Invest (2018) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 3d
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples (fig 3d). Clin Exp Immunol (2018) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 5h, 6k
BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on human samples (fig 5h, 6k). Cancer Res (2018) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 1b
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples (fig 1b). J Clin Invest (2018) ncbi
mouse monoclonal (EH12.2H7)
  • immunohistochemistry - frozen section; human; fig 1a
  • flow cytometry; human; fig 1b
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in immunohistochemistry - frozen section on human samples (fig 1a) and in flow cytometry on human samples (fig 1b). J Exp Med (2018) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; hamsters; loading ...; fig s5
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on hamsters samples (fig s5). MAbs (2018) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; fig s2e
BioLegend PDCD1 antibody (BioLegend, 329913) was used in flow cytometry on human samples (fig s2e). Cell (2018) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; fig s2k
In order to investigate the role of dopamine in B cell maturation in germinal centres, BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples (fig s2k). Nature (2017) ncbi
mouse monoclonal (EH12.2H7)
  • mass cytometry; human; loading ...; fig 2a
In order to investigate the immune composition of tumor microenvironment in hepatocellular carcinoma, BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in mass cytometry on human samples (fig 2a). Proc Natl Acad Sci U S A (2017) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig st1
In order to investigate the effect of PD-1 expression on phagocytosis and tumour immunity, BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on human samples (fig st1). Nature (2017) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; tbl s3
In order to conduct a phenotypical investigation of clear cell renal cell carcinoma, BioLegend PDCD1 antibody (biolegend, EH12.2H7) was used in flow cytometry on human samples (tbl s3). Cell (2017) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 5b
In order to find a role for IL-4 in promoting breast cancer aggressiveness, BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on human samples (fig 5b). Cancer Res (2017) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; African green monkey; loading ...; fig s4
In order to optimize the dosing regimen of neutralizing anti-HIV-1 antibodies, BioLegend PDCD1 antibody (biolegend, EH12.2H7) was used in flow cytometry on African green monkey samples (fig s4). Nature (2017) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig s2a
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples (fig s2a). Immun Ageing (2017) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; tbl s9
In order to optimize and assess potential malaria vaccine regimens, BioLegend PDCD1 antibody (BioLegend, 329920) was used in flow cytometry on human samples (tbl s9). Nature (2017) ncbi
mouse monoclonal (EH12.2H7)
In order to elucidate the interaction between tumor-associated and -infiltrating lymphocytes in ovarian cancer, BioLegend PDCD1 antibody (Biolegend, 329919) was used . Oncoimmunology (2017) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; Rhesus monkey; fig s4f
In order to study CXCR5+ CD8 T cells in SIV-infected animals, BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on Rhesus monkey samples (fig s4f). Proc Natl Acad Sci U S A (2017) ncbi
mouse monoclonal (EH12.2H7)
  • immunohistochemistry - frozen section; human; 1:100
  • flow cytometry; human
In order to characterize activated T cells in joint tissue from patients with rheumatoid arthritis, BioLegend PDCD1 antibody (biolegend, EH12.2H7) was used in immunohistochemistry - frozen section on human samples at 1:100 and in flow cytometry on human samples . Nature (2017) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...
In order to show T cell immunoglobulin and ITIM domain expression increases over time despite early initiation of antiretroviral treatment, BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on human samples . Sci Rep (2017) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; mouse; loading ...; fig 3a
In order to study the impact of modulating IFN-I signaling during suppressive combined antiretroviral therapy, BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on mouse samples (fig 3a). J Clin Invest (2017) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig s2b
In order to characterize gammadelta T cell subsets from healthy humans, BioLegend PDCD1 antibody (biolegend, EH12.2H7) was used in flow cytometry on human samples (fig s2b). Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig s8
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples (fig s8). Science (2016) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; Rhesus monkey; loading ...; fig s11c
In order to assess the efficacy of targeting alpha4 beta7 integrin to treat SIV, BioLegend PDCD1 antibody (BioLegend, 329916) was used in flow cytometry on Rhesus monkey samples (fig s11c). Science (2016) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig s3a
In order to identify and characterize CXCR5hiCD44hiCD8 T cells in HIV-infected individuals, BioLegend PDCD1 antibody (Biolegend, 329908) was used in flow cytometry on human samples (fig s3a). PLoS Pathog (2016) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 1a
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples (fig 1a). J Clin Invest (2016) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; fig s9b
In order to explore the role of exhausted CD8 positive CXCR5 positive T cells in mice chronically infected with lymphocytic choriomeningitis virus, BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on human samples (fig s9b). Nature (2016) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 3b
In order to utilize humanized major histocompatibility class I- and class II-deficient NOG mice to assess the antitumor effect of an anti-programmed death-1 antibody, BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples (fig 3b). Clin Cancer Res (2017) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; Rhesus monkey; loading ...
In order to optimize vaccination with Aventis Pasteur's canarypox vector-HIV, BioLegend PDCD1 antibody (BioLegend, 329924) was used in flow cytometry on Rhesus monkey samples . Nat Med (2016) ncbi
mouse monoclonal (EH12.2H7)
BioLegend PDCD1 antibody (BioLegend, 329904) was used . EMBO Mol Med (2016) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig s3
BioLegend PDCD1 antibody (Biolegend, EH12-2HT) was used in flow cytometry on human samples (fig s3). Nature (2016) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 3
In order to study the pharmacologic inhibition of PI3K and MEK pathways in mixed cultures of human mononuclear cells., BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples (fig 3). Am J Transplant (2016) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; fig 3??
In order to assess the impact of neoantigen intratumor heterogeneity on antitumor immunity, BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on human samples (fig 3??). Science (2016) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; fig 4, 5
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples (fig 4, 5). PLoS Pathog (2016) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; fig 1a
In order to analyze HIV progression traits of a selective loss of early differentiated and highly functional PD1high CD4 T cells, BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples (fig 1a). PLoS ONE (2015) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; Rhesus monkey; loading ...; fig 5a
In order to study the CD8+ non-cytolytic antiviral response in SIV infected rhesus macaques, BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on Rhesus monkey samples (fig 5a). PLoS ONE (2015) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 2a
In order to demonstrate that TGF-beta induces the differentiation of human CXCL13-producing CD4 positive T cells from naive CD4 positive T cells, BioLegend PDCD1 antibody (BioLegend, EH12.2.H7) was used in flow cytometry on human samples (fig 2a). Eur J Immunol (2016) ncbi
mouse monoclonal (EH12.2H7)
BioLegend PDCD1 antibody (BioLegend, 329908) was used . Nat Commun (2015) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; fig 1
In order to assess the CD4/CD8 ratio as a marker for CD4+ T cell dysfunction in chronic HIV infection, BioLegend PDCD1 antibody (Biolegend, clone EH12.2H7) was used in flow cytometry on human samples (fig 1). PLoS ONE (2015) ncbi
mouse monoclonal (EH12.2H7)
  • blocking or activating experiments; human; fig 8
BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in blocking or activating experiments on human samples (fig 8). PLoS Pathog (2015) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human
BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on human samples . Clin Immunol (2015) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human
In order to determine if HIV elite controllers have exhausted T cells, BioLegend PDCD1 antibody (Biolegend, EH12.2 H7) was used in flow cytometry on human samples . J Infect Dis (2015) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; African green monkey; fig s4a
In order to describe the functional characteristics and dynamics of T cells in individual granulomas, BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on African green monkey samples (fig s4a). PLoS Pathog (2015) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples . Hum Immunol (2015) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples . Int J Oncol (2015) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; Rhesus monkey
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on Rhesus monkey samples . J Immunol (2014) ncbi
mouse monoclonal (EH12.2H7)
  • blocking or activating experiments; human
BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in blocking or activating experiments on human samples . J Hepatol (2015) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; Rhesus monkey
BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on Rhesus monkey samples . Antimicrob Agents Chemother (2014) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples . J Immunol (2014) ncbi
mouse monoclonal (EH12.2H7)
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used . Clin Cancer Res (2014) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples . J Immunol (2014) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human
BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on human samples . PLoS Pathog (2014) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; Rhesus monkey; loading ...; fig s1c
In order to explore germinal center-related hyperimmune responses and disease severity during viral infection, BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on Rhesus monkey samples (fig s1c). J Immunol (2014) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human
In order to determine the presence, frequency, association to other immune parameters, and functional properties of circulating CD14(+) cells lacking HLA-DR expression in patients with untreated chronic lymphocytic leukemia, BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on human samples . Blood (2014) ncbi
mouse monoclonal (EH12.2H7)
  • immunocytochemistry; human
BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in immunocytochemistry on human samples . Eur J Immunol (2014) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples . J Immunol (2014) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; 0.7:100
BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on human samples at 0.7:100. J Clin Invest (2014) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples . PLoS ONE (2014) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human
In order to examine human differentiated effector CD4(+) T cells that are defined by low levels of IL-2 and IL-7 receptors, BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples . Cancer Res (2014) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 1
In order to discuss the importance of assessing immune competence in cancer patients, BioLegend PDCD1 antibody (Biolegend, EH12.1) was used in flow cytometry on human samples (fig 1). Cancer Immunol Immunother (2014) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples . Clin Cancer Res (2012) ncbi
Invitrogen
mouse monoclonal (eBioJ105 (J105))
  • flow cytometry; human; loading ...; fig 1c
Invitrogen PDCD1 antibody (eBioscience, eBIOJ105) was used in flow cytometry on human samples (fig 1c). Nat Med (2019) ncbi
mouse monoclonal (eBioJ105 (J105))
  • flow cytometry; human; loading ...; fig s10b
Invitrogen PDCD1 antibody (eBiosciences, J105) was used in flow cytometry on human samples (fig s10b). Nature (2017) ncbi
mouse monoclonal (eBioJ105 (J105))
  • flow cytometry; human; loading ...; fig 1a
In order to study the restoration of immune function in chronic HIV infection, Invitrogen PDCD1 antibody (eBioscience, ebioJ105) was used in flow cytometry on human samples (fig 1a). J Clin Invest (2017) ncbi
mouse monoclonal (eBioJ105 (J105))
  • flow cytometry; human; loading ...; tbl 1
In order to demonstrate that freezing already-stained samples suspended in 10% DMSO in FBS is practical and efficient way to preserve already-stained samples for mass cytometry assessment, Invitrogen PDCD1 antibody (eBioscience, eBioJ105) was used in flow cytometry on human samples (tbl 1). Cytometry A (2017) ncbi
mouse monoclonal (eBioJ105 (J105))
  • flow cytometry; human; loading ...; fig 1
Invitrogen PDCD1 antibody (eBioscience, J105) was used in flow cytometry on human samples (fig 1). Stem Cells Int (2016) ncbi
mouse monoclonal (eBioJ105 (J105))
  • flow cytometry; human; loading ...; fig 1a
In order to generate adenoviral vaccines that express HPV-16 E6 and E7 epitopes alone or fused with p16 and assess immune responses, Invitrogen PDCD1 antibody (eBioscience, J105) was used in flow cytometry on human samples (fig 1a). J Immunol (2016) ncbi
mouse monoclonal (eBioJ105 (J105))
  • flow cytometry; African green monkey; fig 1
In order to study lymph node-resident simian immunodeficiency virus env-specific T follicular helper cells due to vaccine induction in Rhesus Macaques, Invitrogen PDCD1 antibody (eBioscience, eBioJ105) was used in flow cytometry on African green monkey samples (fig 1). J Immunol (2016) ncbi
mouse monoclonal (eBioJ105 (J105))
  • flow cytometry; human; 1:10
In order to utilize mass cytometry for multiplexed peptide-MHC tetramer staining, Invitrogen PDCD1 antibody (eBioscience, eBioJ105) was used in flow cytometry on human samples at 1:10. Methods Mol Biol (2015) ncbi
mouse monoclonal (eBioJ105 (J105))
  • flow cytometry; marmosets; loading ...; fig 4b
In order to test a therapeutic antibody against CD127 in a mouse model of experimental autoimmune encephalomyelitis, Invitrogen PDCD1 antibody (Ebiosciences, J105) was used in flow cytometry on marmosets samples (fig 4b). J Neuroimmune Pharmacol (2016) ncbi
mouse monoclonal (eBioJ105 (J105))
  • blocking or activating experiments; human; fig 1
Invitrogen PDCD1 antibody (eBioscience, J105) was used in blocking or activating experiments on human samples (fig 1). Nat Commun (2015) ncbi
mouse monoclonal (eBioJ105 (J105))
  • flow cytometry; Rhesus monkey; loading ...; fig 2a
In order to assess early changes in CD4 and CD8 T cells in rhesus macaques infected with SIVMAC251, Invitrogen PDCD1 antibody (eBioscience, J105) was used in flow cytometry on Rhesus monkey samples (fig 2a). J Virol (2014) ncbi
mouse monoclonal (eBioJ105 (J105))
  • flow cytometry; human; fig 2a
In order to test if low immune activation contributes to the viremic slow progressor phenotype, Invitrogen PDCD1 antibody (eBioscience, eBioJ105) was used in flow cytometry on human samples (fig 2a). AIDS Res Hum Retroviruses (2013) ncbi
mouse monoclonal (eBioJ105 (J105))
  • flow cytometry; human; loading ...; fig 3b
In order to study the role of T regulatory cells in HIV infection, Invitrogen PDCD1 antibody (eBioscience, eBioJ105) was used in flow cytometry on human samples (fig 3b). J Virol (2011) ncbi
Articles Reviewed
  1. Celis Gutierrez J, Blattmann P, Zhai Y, Jarmuzynski N, Ruminski K, Gregoire C, et al. Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy. Cell Rep. 2019;27:3315-3330.e7 pubmed publisher
  2. Thauland T, Pellerin L, Ohgami R, Bacchetta R, Butte M. Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome. Front Immunol. 2019;10:753 pubmed publisher
  3. Wagner J, Rapsomaniki M, Chevrier S, Anzeneder T, Langwieder C, Dykgers A, et al. A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer. Cell. 2019;177:1330-1345.e18 pubmed publisher
  4. Amelio P, Portevin D, Hella J, Reither K, Kamwela L, Lweno O, et al. HIV Infection Functionally Impairs Mycobacterium tuberculosis-Specific CD4 and CD8 T-Cell Responses. J Virol. 2019;93: pubmed publisher
  5. Scheper W, Kelderman S, Fanchi L, Linnemann C, Bendle G, de Rooij M, et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat Med. 2019;25:89-94 pubmed publisher
  6. Andre P, Denis C, Soulas C, Bourbon Caillet C, Lopez J, Arnoux T, et al. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells. Cell. 2018;175:1731-1743.e13 pubmed publisher
  7. Dias J, Boulouis C, Gorin J, van den Biggelaar R, Lal K, Gibbs A, et al. The CD4-CD8- MAIT cell subpopulation is a functionally distinct subset developmentally related to the main CD8+ MAIT cell pool. Proc Natl Acad Sci U S A. 2018;115:E11513-E11522 pubmed publisher
  8. Deng M, Gui X, Kim J, Xie L, Chen W, Li Z, et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature. 2018;562:605-609 pubmed publisher
  9. Burton A, Pallett L, McCoy L, Suveizdyte K, Amin O, Swadling L, et al. Circulating and intrahepatic antiviral B cells are defective in hepatitis B. J Clin Invest. 2018;128:4588-4603 pubmed publisher
  10. Hartana C, Ahlén Bergman E, Broome A, Berglund S, Johansson M, Alamdari F, et al. Tissue-resident memory T cells are epigenetically cytotoxic with signs of exhaustion in human urinary bladder cancer. Clin Exp Immunol. 2018;194:39-53 pubmed publisher
  11. Jung I, Kim Y, Yu H, Lee M, Kim S, Lee J. CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells. Cancer Res. 2018;78:4692-4703 pubmed publisher
  12. Moysi E, Pallikkuth S, de Armas L, Gonzalez L, Ambrozak D, George V, et al. Altered immune cell follicular dynamics in HIV infection following influenza vaccination. J Clin Invest. 2018;128:3171-3185 pubmed publisher
  13. Sayin I, Radtke A, Vella L, Jin W, Wherry E, Buggert M, et al. Spatial distribution and function of T follicular regulatory cells in human lymph nodes. J Exp Med. 2018;215:1531-1542 pubmed publisher
  14. Adler A, Bedinger D, Adams M, Asensio M, Edgar R, Leong R, et al. A natively paired antibody library yields drug leads with higher sensitivity and specificity than a randomly paired antibody library. MAbs. 2018;10:431-443 pubmed publisher
  15. Gee M, Han A, Lofgren S, Beausang J, Mendoza J, Birnbaum M, et al. Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes. Cell. 2018;172:549-563.e16 pubmed publisher
  16. Burr M, Sparbier C, Chan Y, Williamson J, Woods K, Beavis P, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017;549:101-105 pubmed publisher
  17. Papa I, Saliba D, Ponzoni M, Bustamante S, Canete P, Gonzalez Figueroa P, et al. TFH-derived dopamine accelerates productive synapses in germinal centres. Nature. 2017;547:318-323 pubmed publisher
  18. Chew V, Lai L, Pan L, Lim C, Li J, Ong R, et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci U S A. 2017;114:E5900-E5909 pubmed publisher
  19. Gordon S, Maute R, Dulken B, Hutter G, George B, McCracken M, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545:495-499 pubmed publisher
  20. Chevrier S, Levine J, Zanotelli V, Silina K, Schulz D, Bacac M, et al. An Immune Atlas of Clear Cell Renal Cell Carcinoma. Cell. 2017;169:736-749.e18 pubmed publisher
  21. Gaggianesi M, Turdo A, Chinnici A, Lipari E, Apuzzo T, Benfante A, et al. IL4 Primes the Dynamics of Breast Cancer Progression via DUSP4 Inhibition. Cancer Res. 2017;77:3268-3279 pubmed publisher
  22. Nishimura Y, Gautam R, Chun T, Sadjadpour R, Foulds K, Shingai M, et al. Early antibody therapy can induce long-lasting immunity to SHIV. Nature. 2017;543:559-563 pubmed publisher
  23. van der Geest K, Wang Q, Eijsvogels T, Koenen H, Joosten I, Brouwer E, et al. Changes in peripheral immune cell numbers and functions in octogenarian walkers - an acute exercise study. Immun Ageing. 2017;14:5 pubmed publisher
  24. Mordmuller B, Surat G, Lagler H, Chakravarty S, Ishizuka A, Lalremruata A, et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature. 2017;542:445-449 pubmed publisher
  25. Huang R, Francois A, McGray A, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology. 2017;6:e1249561 pubmed publisher
  26. Mylvaganam G, Rios D, Abdelaal H, Iyer S, Tharp G, Mavigner M, et al. Dynamics of SIV-specific CXCR5+ CD8 T cells during chronic SIV infection. Proc Natl Acad Sci U S A. 2017;114:1976-1981 pubmed publisher
  27. Rao D, Gurish M, Marshall J, Slowikowski K, Fonseka C, Liu Y, et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature. 2017;542:110-114 pubmed publisher
  28. Tauriainen J, Scharf L, Frederiksen J, Naji A, Ljunggren H, Sonnerborg A, et al. Perturbed CD8+ T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals. Sci Rep. 2017;7:40354 pubmed publisher
  29. Cheng L, Ma J, Li J, Li D, Li G, Li F, et al. Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs. J Clin Invest. 2017;127:269-279 pubmed publisher
  30. Zhen A, Rezek V, Youn C, Lam B, Chang N, Rick J, et al. Targeting type I interferon-mediated activation restores immune function in chronic HIV infection. J Clin Invest. 2017;127:260-268 pubmed publisher
  31. Ryan P, Sumaria N, Holland C, Bradford C, Izotova N, Grandjean C, et al. Heterogeneous yet stable Vδ2(+) T-cell profiles define distinct cytotoxic effector potentials in healthy human individuals. Proc Natl Acad Sci U S A. 2016;113:14378-14383 pubmed
  32. Sumatoh H, Teng K, Cheng Y, Newell E. Optimization of mass cytometry sample cryopreservation after staining. Cytometry A. 2017;91:48-61 pubmed publisher
  33. Sen D, Kaminski J, Barnitz R, Kurachi M, Gerdemann U, Yates K, et al. The epigenetic landscape of T cell exhaustion. Science. 2016;354:1165-1169 pubmed
  34. Byrareddy S, Arthos J, Cicala C, Villinger F, Ortiz K, Little D, et al. Sustained virologic control in SIV+ macaques after antiretroviral and α4β7 antibody therapy. Science. 2016;354:197-202 pubmed
  35. Miles B, Miller S, Folkvord J, Levy D, Rakasz E, Skinner P, et al. Follicular Regulatory CD8 T Cells Impair the Germinal Center Response in SIV and Ex Vivo HIV Infection. PLoS Pathog. 2016;12:e1005924 pubmed publisher
  36. Daud A, Loo K, Pauli M, Sanchez Rodriguez R, Sandoval P, Taravati K, et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest. 2016;126:3447-52 pubmed publisher
  37. He R, Hou S, Liu C, Zhang A, Bai Q, Han M, et al. Follicular CXCR5- expressing CD8(+) T cells curtail chronic viral infection. Nature. 2016;537:412-428 pubmed publisher
  38. Ashizawa T, Iizuka A, Nonomura C, Kondou R, Maeda C, Miyata H, et al. Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse. Clin Cancer Res. 2017;23:149-158 pubmed publisher
  39. Vaccari M, Gordon S, Fourati S, Schifanella L, Liyanage N, Cameron M, et al. Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nat Med. 2016;22:762-70 pubmed publisher
  40. Jin C, Fotaki G, Ramachandran M, Nilsson B, Essand M, Yu D. Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer. EMBO Mol Med. 2016;8:702-11 pubmed publisher
  41. Ruibal P, Oestereich L, Lüdtke A, Becker Ziaja B, Wozniak D, Kerber R, et al. Unique human immune signature of Ebola virus disease in Guinea. Nature. 2016;533:100-4 pubmed publisher
  42. Saito H, Okita K, Fusaki N, Sabel M, Chang A, Ito F. Reprogramming of Melanoma Tumor-Infiltrating Lymphocytes to Induced Pluripotent Stem Cells. Stem Cells Int. 2016;2016:8394960 pubmed publisher
  43. Zwang N, Zhang R, Germana S, Fan M, Hastings W, Cao A, et al. Selective Sparing of Human Tregs by Pharmacologic Inhibitors of the Phosphatidylinositol 3-Kinase and MEK Pathways. Am J Transplant. 2016;16:2624-38 pubmed publisher
  44. McGranahan N, Furness A, Rosenthal R, Ramskov S, Lyngaa R, Saini S, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463-9 pubmed publisher
  45. Garcia Bates T, Kim E, Concha Benavente F, Trivedi S, Mailliard R, Gambotto A, et al. Enhanced Cytotoxic CD8 T Cell Priming Using Dendritic Cell-Expressing Human Papillomavirus-16 E6/E7-p16INK4 Fusion Protein with Sequenced Anti-Programmed Death-1. J Immunol. 2016;196:2870-8 pubmed publisher
  46. Vargas Inchaustegui D, Demers A, Shaw J, Kang G, Ball D, Tuero I, et al. Vaccine Induction of Lymph Node-Resident Simian Immunodeficiency Virus Env-Specific T Follicular Helper Cells in Rhesus Macaques. J Immunol. 2016;196:1700-10 pubmed publisher
  47. Yasuma K, Yasunaga J, Takemoto K, Sugata K, Mitobe Y, Takenouchi N, et al. HTLV-1 bZIP Factor Impairs Anti-viral Immunity by Inducing Co-inhibitory Molecule, T Cell Immunoglobulin and ITIM Domain (TIGIT). PLoS Pathog. 2016;12:e1005372 pubmed publisher
  48. Paris R, Petrovas C, Ferrando Martinez S, Moysi E, Boswell K, Archer E, et al. Selective Loss of Early Differentiated, Highly Functional PD1high CD4 T Cells with HIV Progression. PLoS ONE. 2015;10:e0144767 pubmed publisher
  49. Javed A, Leuchte N, Neumann B, Sopper S, Sauermann U. Noncytolytic CD8+ Cell Mediated Antiviral Response Represents a Strong Element in the Immune Response of Simian Immunodeficiency Virus-Infected Long-Term Non-Progressing Rhesus Macaques. PLoS ONE. 2015;10:e0142086 pubmed publisher
  50. Leong M, Newell E. Multiplexed Peptide-MHC Tetramer Staining with Mass Cytometry. Methods Mol Biol. 2015;1346:115-31 pubmed publisher
  51. Kobayashi S, Watanabe T, Suzuki R, Furu M, Ito H, Ito J, et al. TGF-β induces the differentiation of human CXCL13-producing CD4(+) T cells. Eur J Immunol. 2016;46:360-71 pubmed publisher
  52. Miles B, Miller S, Folkvord J, Kimball A, Chamanian M, Meditz A, et al. Follicular regulatory T cells impair follicular T helper cells in HIV and SIV infection. Nat Commun. 2015;6:8608 pubmed publisher
  53. Frederiksen J, Buggert M, Noyan K, Nowak P, Sönnerborg A, Lund O, et al. Multidimensional Clusters of CD4+ T Cell Dysfunction Are Primarily Associated with the CD4/CD8 Ratio in Chronic HIV Infection. PLoS ONE. 2015;10:e0137635 pubmed publisher
  54. Dunham J, Lee L, van Driel N, Laman J, Ni I, Zhai W, et al. Blockade of CD127 Exerts a Dichotomous Clinical Effect in Marmoset Experimental Autoimmune Encephalomyelitis. J Neuroimmune Pharmacol. 2016;11:73-83 pubmed publisher
  55. Rancan C, Schirrmann L, Hüls C, Zeidler R, Moosmann A. Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells. PLoS Pathog. 2015;11:e1004906 pubmed publisher
  56. Lee J, Jeong I, Joh J, Jung Y, Sim S, Choi B, et al. Differential expression of CD57 in antigen-reactive CD4+ T cells between active and latent tuberculosis infection. Clin Immunol. 2015;159:37-46 pubmed publisher
  57. Pombo C, Wherry E, Gostick E, Price D, Betts M. Elevated Expression of CD160 and 2B4 Defines a Cytolytic HIV-Specific CD8+ T-Cell Population in Elite Controllers. J Infect Dis. 2015;212:1376-86 pubmed publisher
  58. Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, Bell L, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun. 2015;6:6692 pubmed publisher
  59. Gideon H, Phuah J, Myers A, Bryson B, Rodgers M, Coleman M, et al. Variability in tuberculosis granuloma T cell responses exists, but a balance of pro- and anti-inflammatory cytokines is associated with sterilization. PLoS Pathog. 2015;11:e1004603 pubmed publisher
  60. Rueda C, Wells C, Gisslen T, Jobe A, Kallapur S, Chougnet C. Effect of chorioamnionitis on regulatory T cells in moderate/late preterm neonates. Hum Immunol. 2015;76:65-73 pubmed publisher
  61. Sawada Y, Yoshikawa T, Shimomura M, Iwama T, Endo I, Nakatsura T. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. Int J Oncol. 2015;46:28-36 pubmed publisher
  62. Fujita T, Burwitz B, Chew G, Reed J, Pathak R, Seger E, et al. Expansion of dysfunctional Tim-3-expressing effector memory CD8+ T cells during simian immunodeficiency virus infection in rhesus macaques. J Immunol. 2014;193:5576-83 pubmed publisher
  63. Langhans B, Alwan A, Krämer B, Glässner A, Lutz P, Strassburg C, et al. Regulatory CD4+ T cells modulate the interaction between NK cells and hepatic stellate cells by acting on either cell type. J Hepatol. 2015;62:398-404 pubmed publisher
  64. Del Prete G, Shoemaker R, Oswald K, Lara A, Trubey C, Fast R, et al. Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques. Antimicrob Agents Chemother. 2014;58:6790-806 pubmed publisher
  65. Herati R, Reuter M, Dolfi D, Mansfield K, Aung H, Badwan O, et al. Circulating CXCR5+PD-1+ response predicts influenza vaccine antibody responses in young adults but not elderly adults. J Immunol. 2014;193:3528-37 pubmed publisher
  66. Ohue Y, Kurose K, Mizote Y, Matsumoto H, Nishio Y, Isobe M, et al. Prolongation of overall survival in advanced lung adenocarcinoma patients with the XAGE1 (GAGED2a) antibody. Clin Cancer Res. 2014;20:5052-63 pubmed publisher
  67. Bending D, Pesenacker A, Ursu S, Wu Q, Lom H, Thirugnanabalan B, et al. Hypomethylation at the regulatory T cell-specific demethylated region in CD25hi T cells is decoupled from FOXP3 expression at the inflamed site in childhood arthritis. J Immunol. 2014;193:2699-708 pubmed publisher
  68. Buggert M, Tauriainen J, Yamamoto T, Frederiksen J, Ivarsson M, Michaelsson J, et al. T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection. PLoS Pathog. 2014;10:e1004251 pubmed publisher
  69. Kenway Lynch C, Das A, Lackner A, Pahar B. Cytokine/Chemokine responses in activated CD4+ and CD8+ T cells isolated from peripheral blood, bone marrow, and axillary lymph nodes during acute simian immunodeficiency virus infection. J Virol. 2014;88:9442-57 pubmed publisher
  70. Hong J, Amancha P, Rogers K, Courtney C, Havenar Daughton C, Crotty S, et al. Early lymphoid responses and germinal center formation correlate with lower viral load set points and better prognosis of simian immunodeficiency virus infection. J Immunol. 2014;193:797-806 pubmed publisher
  71. Jitschin R, Braun M, Büttner M, Dettmer Wilde K, Bricks J, Berger J, et al. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood. 2014;124:750-60 pubmed publisher
  72. Gautron A, Dominguez Villar M, de Marcken M, Hafler D. Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells. Eur J Immunol. 2014;44:2703-2711 pubmed publisher
  73. Buggert M, Norstr m M, Salemi M, Hecht F, Karlsson A. Functional avidity and IL-2/perforin production is linked to the emergence of mutations within HLA-B*5701-restricted epitopes and HIV-1 disease progression. J Immunol. 2014;192:4685-96 pubmed publisher
  74. Gros A, Robbins P, Yao X, Li Y, Turcotte S, Tran E, et al. PD-1 identifies the patient-specific CD8? tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014;124:2246-59 pubmed publisher
  75. Lanteri M, Diamond M, Law J, Chew G, Wu S, Inglis H, et al. Increased frequency of Tim-3 expressing T cells is associated with symptomatic West Nile virus infection. PLoS ONE. 2014;9:e92134 pubmed publisher
  76. Peguillet I, Milder M, Louis D, Vincent Salomon A, Dorval T, Piperno Neumann S, et al. High numbers of differentiated effector CD4 T cells are found in patients with cancer and correlate with clinical response after neoadjuvant therapy of breast cancer. Cancer Res. 2014;74:2204-16 pubmed publisher
  77. Chang S, Kohrt H, Maecker H. Monitoring the immune competence of cancer patients to predict outcome. Cancer Immunol Immunother. 2014;63:713-9 pubmed publisher
  78. Radvanyi L, Bernatchez C, Zhang M, Fox P, Miller P, Chacon J, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012;18:6758-70 pubmed publisher
  79. Shaw J, Hunt P, Critchfield J, McConnell D, Garcia J, Pollard R, et al. Short communication: HIV+ viremic slow progressors maintain low regulatory T cell numbers in rectal mucosa but exhibit high T cell activation. AIDS Res Hum Retroviruses. 2013;29:172-7 pubmed publisher
  80. Shaw J, Hunt P, Critchfield J, McConnell D, Garcia J, Pollard R, et al. Increased frequency of regulatory T cells accompanies increased immune activation in rectal mucosae of HIV-positive noncontrollers. J Virol. 2011;85:11422-34 pubmed publisher